Objectives: To investigate the feasibility and pharmacokinetics of a once-daily regimen of 2000 mg saquinavir mesylate boosted with 100 mg ritonavir.
Introduction
Ritonavir-boosted saquinavir is a frequently used and widely available protease inhibitor (PI) for the initial and salvage treatment of HIV disease. Most PIs are metabolized via cytochrome P450 isoenzymes, mainly by CYP3A4 and to a lesser extent by CYP2C9 and CYP2D6. 1 Ritonavir primarily inhibits the metabolism of drugs by CYP3A4 and to a lesser extent by CYP2D6. 2 For PIs that undergo a high first-pass metabolism, such as saquinavir, the booster effect of low-dose ritonavir is principally caused by an elevation of both maximum and minimum plasma concentrations (C max and C min ). Therefore the combination of low doses of ritonavir enables the reduction of saquinavir doses as well as the dosing frequency. Several studies have shown that even a once-daily dosing of ritonavir/saquinavir is safe and effective. 3 -7 Most of these studies used the two older saquinavir formulations (hard or soft gel capsules) with 200 mg strength per capsule in combination with low-dose ritonavir. Once the new saquinavir mesylate formulation with 500 mg strength per pill was approved in December 2004 the pill burden decreased again; however, it limits the variability of previously used dosing schedules. The aim of our analysis was to investigate the feasibility of a once-daily regimen of 2000 mg saquinavir mesylate boosted with 100 mg ritonavir.
Patients and methods

Study design
This was a pharmacokinetic observation including HIV-1-infected patients successfully treated with 1000 mg saquinavir mesylate/ 100 mg ritonavir twice daily in combination with two nucleoside or nucleotide reverse transcriptase inhibitors [N(t)RTIs]. Patients in a stable condition with an HIV-RNA PCR of ,50 copies/mL who were switched to the once-daily regimen of 2000 mg saquinavir mesylate boosted with 100 mg ritonavir to simplify the treatment schedule were included in the analysis. All patients received the saquinavir in its mesylate formulation with 500 mg strength per pill before and after the switch. Administration of the nucleoside/nucleotide backbone drugs was left unchanged. We observed only patients with no active AIDS defining illness or other severe medical condition requiring urgent treatment and no concurrent medication besides HIV treatment that could cause a drug-drug interaction was allowed. Patients gave verbal informed consent to be evaluated in this analysis. All ethical standards were observed and adhered to, in accordance with local criteria.
Therapeutic drug monitoring protocol
At the time of the first pharmacokinetic assessment (PK1 ¼ baseline), all concomitant medication was recorded. After at least 2 weeks on stable therapy, patients underwent a pharmacokinetic assessment following a standardized protocol at steady-state conditions. The schedule of drug intake was documented by the patients for 3 days prior to the pharmacokinetic assessment. In addition, all concomitant drugs had to be documented by the patient and physician, including daily intake of herbal agents or nutritive supplements. On the day of the pharmacokinetic assessment, fasting trough levels were obtained immediately before drug intake, followed by a standardized breakfast of 2500 kJ (25% from fat). Plasma samples were then collected at 1, 2, 4, 6, 9 and 12 h after the drug intake. 8 After PK1 all patients were switched from 1000 mg saquinavir/ 100 mg ritonavir twice daily to 2000 mg saquinavir/100 mg ritonavir once daily with unchanged N(t)RTI backbone therapy. Three weeks after the switch a second pharmacokinetic assessment (PK2) was scheduled as described above. For PK2 an additional sample was taken 24 h after the drug intake. The blood samples were centrifuged at 1500 rpm for 10 min and serum was stored at 2808C prior to analysis.
Pharmacokinetic assay and evaluation
Saquinavir and ritonavir serum concentrations were measured by validated HPLC-tandem mass spectrometry methods (equipment from Merck-Hitachi, Germany and Applied Biosystems/Canada at Therapia GmbH, Berlin, Germany), described previously. 9 The reliable lower limit of quantification (LLQ) was 20 ng/mL and linearity of the calibration curve for all tested compounds was proved up to 20 000 ng/mL. Pharmacokinetic calculations were based on plasma concentrations that exceeded the LLQ. The C min and C max values of the non-compartmental analysis represent the lowest and the highest plasma drug concentrations observed over the standard 12 h dosing interval and were read directly from the plasma concentration-time curves of saquinavir and ritonavir within the standard dosing interval (t ¼0 -12 or 0-24 h). The time until C max was defined as T max . The area under the plasma concentration -time curve, AUC t , at steady state was obtained by using a non-compartmental analysis module. In order to compare the AUC 0 -12 with the AUC 0 -24 , the AUC 0 -12 was doubled, assuming linearity of saquinavir kinetics. At 3, 6, 9 and 12 months fasting metabolic parameters, clinical chemistry, CD4 cell count and an HIV-RNA PCR were taken.
Statistical methods
The primary target variables, C min , C max , AUC t and T max , of saquinavir and ritonavir were compared between the study periods by means of parametric t-tests. The absence of a significant difference of the saquinavir and ritonavir exposure between groups was suggested when no significant difference (at a 0.05 level) of the geometric mean ratio (GMR), together with a 90% confidence interval (CI), was determined (SPSS 15.0 for Windows w ), following the FDA recommendations for the conduct of clinical pharmacokinetic studies. 10 Other parameters are shown as median values with the according standard deviation unless otherwise noted.
Results
Eighteen patients (two female) were analysed. The demographic characteristics of the study subjects are summarized in Table 1 . The patients were middle-aged, 50% had AIDS and the patients had a low CD4 nadir and a high pre-treatment HIV-RNA PCR. At baseline CD4 cells were relatively high with a median of 464 cells/mm 3 , the HIV-RNA PCR was ,50 copies/mL and the body mass index (BMI) was in the normal range with a median of 21.5 kg/m 2 . Median time (range) on saquinavir-containing antiretroviral therapy was 15.9 months (1.5 -105). Median time (range) between PK1 at baseline and the second pharmacokinetic assessment (PK2) was 3.3 weeks (2-13). The N(t)RTI backbone was 245 mg tenofovir disoproxil fumarate/200 mg emtricitabine for 12 patients and 600 mg abacavir/300 mg lamivudine for 6 patients, both taken once daily as a fixed-dose combination. All 18 patients participated in PK1 and PK2. Two patients stopped saquinavir during the 48 week observational period. One patient switched to nevirapine because of cholesterol elevation [10% increase in total cholesterol, low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol]; the other patient switched shortly after PK2 to 400 mg lopinavir/100 mg ritonavir twice daily as a fixed-dose combination to lower his pill burden per intake. Both patients had an HIV-RNA PCR of ,50 copies/mL at the time of the switch. The HIV-RNA PCR of the remaining 16 patients was ,500 copies/mL during the entire 48 week observational period. Four patients experienced a single blip of the HIV-RNA PCR (66 -187 copies/mL), but the HIV-RNA PCR went back to ,50 copies/mL without intervention in all four. Thus no virological breakthrough occurred within the 48 weeks of follow-up. The CD4 cell count increased slightly and the fasting metabolic parameters remained unchanged (summarized in Table 2 ). No grade 3 -4 clinical or laboratory adverse event was recorded.
After switching from 1000 mg saquinavir/100 mg ritonavir twice daily to 2000 mg saquinavir/100 mg ritonavir once daily, the geometric mean AUC 0 -24 for saquinavir decreased marginally from 35 000 to 34490 ng . h/mL (GMR ¼ 0.99; P ¼ 0.426). For saquinavir, the C min fell significantly from 346 to 73 ng/mL (GMR ¼ 0.21; P ¼ 0.009), the C max (2819 to 4058 ng/mL) increased significantly (GMR ¼ 1.40; P ¼ 0.032), and the T max (3.45 to 4.51 h) increased without reaching statistical significance (GMR ¼ 1.30; P ¼ 0.370) after the switch from twice to once daily. In contrast, for ritonavir, the AUC 0 -24 (21 874 to 10267 ng . h/mL, GMR ¼ 0.47; P, 0.001), the C min (330 to 45 ng/mL, GMR ¼0.14; P, 0.001) and the C max (1582 to 1089 ng/mL, GMR ¼0.69; P ¼ 0.057) decreased and the T max (3.55 to 4.85, GMR¼ 1.37; P ¼ 0.043) increased when compared between PK1 and PK2. Table 3 shows a summary of the pharmacokinetic assessment and Figure 1 shows the concentrations over time.
Comparing the first 12 h of PK2, i.e. during once-daily dosing of saquinavir/ritonavir, with PK1, the analysis showed a smaller, but nevertheless statistically significant difference of the geometric mean of saquinavir C min (95 versus 346 ng/mL; P ¼ 0.009), whereas the AUC (25 916 versus 17500 ng . h/mL; P ¼ 0.098) showed a marked but statistically non-significant change. Saquinavir C max (4058 versus 2819 ng/mL; P ¼ 0.032) remained the same as reported above.
Comparing patients who have experienced a blip with those who never had an HIV-RNA PCR of .50 copies/mL, the saquinavir C min (99 versus 110 ng/mL, P ¼ 0.8) and C max (4210 versus 4545 ng/mL, P ¼ 0.7) and AUC 0 -24 (38621 versus 35 496 ng . h/mL, P ¼ 0.8) were not different. Five of the 18 patients had a saquinavir trough level of ,50 ng/mL, which is thought to be the clinical cut-off to inhibit 50% of wild-type HIV, but only one of these five patients had a single blip and none had virological failure.
Discussion
After switching from 1000 mg saquinavir/100 mg ritonavir twice daily to 2000 mg saquinavir/100 mg ritonavir once daily the ritonavir drug exposure decreases significantly without a significant change in the saquinavir AUC 0 -24. The optimal saquinavir dose for once-daily regimens is still not yet defined and shows large variation depending on the body weight, gender and ethnicity of the subjects studied.
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Autar et al. 3 studied 2000 mg saquinavir/100 mg ritonavir and found the saquinavir AUC 0 -24 was twice as high as our results. Likewise Cardiello et al.
4 studied 1600 mg saquinavir/ 100 mg ritonavir once daily and found the saquinavir AUC 0 -24 to be higher compared with our results. In both studies the patients were mostly Thai women with a lower body weight. The combination of pharmacogenomic and environmental/lifestyle factors associated with ethnicity is likely to explain the differences. Ford et al.
6 studied 12 Caucasian patients (11 male) treated with 1600 mg saquinavir/100 mg ritonavir once daily and found an AUC 0 -24 of saquinavir comparable to our findings. Marin-Niebla et al.
7 studied the so-far lowest dose using 1200 mg saquinavir/100 mg ritonavir once daily in 26 mostly male patients and found an AUC 0 -24 of saquinavir similar to our result. But, of note, 53% of the patients had chronic viral hepatitis and 10% liver cirrhosis.
After switching from twice-to once-daily dosing the saquinavir C min decreased significantly. This could be important since time below minimum effective concentration (MEC) could lead to the development of drug resistance and eventually virological breakthrough. Dickinson et al. 5 found that the estimated time below the MEC of saquinavir (100 ng/mL) was highest for 1600/100 once daily followed by 2000/100 once daily compared with 1000/100 twice daily, but, despite the variation in drug exposure found in the above-mentioned studies, virological failure was a rare event throughout all investigations. Ford et al. 6 speculated that a higher C max of once-daily saquinavir could lead to increased intracellular accumulation and this might be the reason for the favourable virological outcome despite drug levels being below the MEC.
Our study has several limitations. Comparison of AUC 0 -24 between the twice-and the once-daily dosing was made using the AUC 0 -12 doubled. This method is limited because it implies that the drug levels do not show diurnal variation. Furthermore, the comparison with other studies is limited, because most of them were conducted with older saquinavir formulations. Slightly different drug levels were obtained when comparing hard and soft gel capsules and saquinavir mesylate. 4, 16 Lastly, the time until drug-resistant virus evolves could be longer than the observed period.
Once-daily treatment is important to improve the adherence to and convenience of highly active antiretroviral therapy. Long-term data for the once-daily use of saquinavir are lacking. Therefore it remains an experimental approach that requires longer follow-up. A 1600 mg dose of saquinavir seems unfeasible with 500 mg pills and 1500 mg saquinavir might be too low for Caucasian males. Thus we believe a dose of 2000 mg saquinavir should be further studied. Up to now atazanavir and darunavir are the only PIs licensed for once-daily use in most countries. But for patients who are already successfully treated with saquinavir or who live in countries with limited resources where newer drugs are not readily available, saquinavir once daily might be a good option. Geometric mean (90% CI) ritonavir plasma concentrations in patients taking saquinavir/ritonavir 1000/100 mg twice daily (n ¼18) versus patients taking saquinavir/ritonavir 2000/100 mg once daily (n ¼18). SQV, saquinavir, BID, twice daily; OD, once daily; RTV, ritonavir.
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